Literature DB >> 27619682

Determination of a CD4+CD25-FoxP3+ T cells subset in tumor-draining lymph nodes of colorectal cancer secreting IL-2 and IFN-γ.

Morteza Jafarinia1,2, Fereshteh Mehdipour1, Seyed Vahid Hosseini3, Leila Ghahramani3, Masood Hosseinzadeh4, Abbas Ghaderi5,6.   

Abstract

CD4+CD25-FoxP3+ cells are a newly recognized subset of T cells which was first reported in autoimmune diseases. In our previous study, this subset was detected in tumor-draining lymph nodes (TDLNs) of patients with breast cancer. As little is known about their function in TDLNs of cancer patients, in this study, their frequency as well as their ability to produce interleukin (IL)-2, IL-10, or interferon (IFN)-γ were investigated in TDLNs of colorectal cancer (CRC) patients. Mononuclear cells were isolated from lymph nodes of 13 patients with CRC using Ficoll-Hypaque gradient centrifugation. Cells were stimulated in vitro and stained with CD25, CD4, FoxP3, IFN-γ, IL-10, and IL-2 or isotype matched antibodies and subjected to flow cytometry. The frequency of CD4+CD25-FoxP3+CD127dim/- cells was significantly lower than CD4+CD25+FoxP3+CD127dim/- population in TDLNs of CRC patients. The percentage of CD127dim/- cells and also the MFI of FoxP3 expression was significantly lower in CD4+CD25-FoxP3+ in comparison with CD4+CD25+FoxP3+ population. Moreover, CD4+CD25-FoxP3+ cells contained higher percentages of IL-2- and IFN-γ-producing cells than CD4+CD25+FoxP3+ subpopulation. But, no difference was seen between two subsets in terms of IL-10 production. CD4+CD25-FoxP3+ cells in TDLNs of CRC patients had lower suppressive and higher effector properties in comparison with CD4+CD25+FoxP3+ conventional regulatory T cells.

Entities:  

Keywords:  CD4+CD25−FoxP3+ cells; Colorectal cancer; Cytokine; Lymph node

Mesh:

Substances:

Year:  2016        PMID: 27619682     DOI: 10.1007/s13277-016-5345-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  31 in total

1.  Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia.

Authors:  Daria Sollazzo; Nicola Polverelli; Francesca Palandri; Nicola Vianelli; Lucia Catani
Journal:  Immunol Lett       Date:  2015-05-02       Impact factor: 3.685

2.  Effects of glucocorticoid treatment on CD25⁻FOXP3⁺ population and cytokine-producing cells in rheumatoid arthritis.

Authors:  Banesa de Paz; Catuxa Prado; Mercedes Alperi-López; Francisco J Ballina-García; Javier Rodriguez-Carrio; Patricia López; Ana Suárez
Journal:  Rheumatology (Oxford)       Date:  2012-03-24       Impact factor: 7.580

3.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

4.  Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.

Authors:  Angela M Thornton; Patricia E Korty; Dat Q Tran; Elizabeth A Wohlfert; Patrick E Murray; Yasmine Belkaid; Ethan M Shevach
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

Review 5.  The functional and prognostic implications of regulatory T cells in colorectal carcinoma.

Authors:  Xinhai Zhang; Sonia Kelaria; Justin Kerstetter; Jun Wang
Journal:  J Gastrointest Oncol       Date:  2015-06

6.  Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes.

Authors:  Zahra Faghih; Nasrollah Erfani; Mohammad Reza Haghshenas; Akbar Safaei; Abdol-Rasoul Talei; Abbas Ghaderi
Journal:  Immunol Lett       Date:  2013-12-08       Impact factor: 3.685

7.  Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus.

Authors:  B Zhang; X Zhang; F L Tang; L P Zhu; Y Liu; P E Lipsky
Journal:  Ann Rheum Dis       Date:  2008-01-16       Impact factor: 19.103

8.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

9.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Authors:  Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

10.  Regulatory T cells in colorectal cancer: from biology to prognostic relevance.

Authors:  Dimitrios Mougiakakos
Journal:  Cancers (Basel)       Date:  2011-03-29       Impact factor: 6.639

View more
  4 in total

1.  Prognostic significance of CD4-positive regulatory T cells in tumor draining lymph nodes from patients with bladder cancer.

Authors:  Ali Ariafar; Yasmin Vahidi; Maryam Fakhimi; Ardalan Asadollahpour; Nasrollah Erfani; Zahra Faghih
Journal:  Heliyon       Date:  2020-12-01

2.  Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation.

Authors:  Julie Jacobs; Vanessa Deschoolmeester; Karen Zwaenepoel; Tal Flieswasser; Christophe Deben; Jolien Van den Bossche; Christophe Hermans; Christian Rolfo; Marc Peeters; Olivier De Wever; Filip Lardon; Vasiliki Siozopoulou; Evelien Smits; Patrick Pauwels
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

3.  The relative change in regulatory T cells / T helper lymphocytes ratio as parameter for prediction of therapy efficacy in metastatic colorectal cancer patients.

Authors:  Tong Xu; Jiezhen Lu; Hanxiang An
Journal:  Oncotarget       Date:  2017-11-21

4.  Helios, CD73 and CD39 Induction in Regulatory T Cells Exposed to Adipose Derived Mesenchymal Stem Cells.

Authors:  Maryam Fakhimi; Abdol Rasoul Talei; Abbas Ghaderi; Mojtaba Habibagahi; Mahboobeh Razmkhah
Journal:  Cell J       Date:  2019-10-14       Impact factor: 2.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.